SCHEDULE 13G: Intracoastal Capital and Affiliates Report Zero Beneficial Ownership in Aptevo Therapeutics After Brief 9.6% Stake

A recent Schedule 13G filing reveals that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC, who briefly held a deemed 9.6% beneficial ownership in Aptevo Therapeutics Inc. on April 3, 2025, reported zero beneficial ownership as of April 9, 2025.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (the "Reporting Persons") filed a Schedule 13G regarding their ownership in Aptevo Therapeutics Inc. common stock.
• On April 3, 2025, immediately following the execution of a Securities Purchase Agreement (SPA) with Aptevo Therapeutics Inc., the Reporting Persons were deemed to have beneficial ownership of 155,000 shares of Common Stock, representing approximately 9.6% of the outstanding shares.
• This 9.6% calculation was based on 1,458,504 shares outstanding as of April 3, 2025, plus the 155,000 shares to be issued to Intracoastal.
• The beneficial ownership calculation excluded 310,000 shares issuable upon exercise of an Intracoastal Warrant, as it is not exercisable until stockholder approval and contains a blocker provision limiting ownership to 4.99%.
• Without the blocker provision and assuming exercisability, the beneficial ownership on April 3, 2025, would have been 465,000 shares.
• As of the close of business on April 9, 2025, the Reporting Persons reported beneficial ownership of 0 shares of Common Stock.
• The 310,000 shares from the Intracoastal Warrant remain unexercisable due to the same conditions (stockholder approval and 4.99% blocker provision).
• The Reporting Persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing ownership changes. While the rapid shift from 9.6% to 0% beneficial ownership by the reporting persons is a significant factual event, the filing itself is neutral in tone and does not offer explicit positive or negative framing from the reporting persons' perspective. The implications of this change are subject to external interpretation.

Positives

• The initial Securities Purchase Agreement (SPA) indicated an investment by Intracoastal Capital LLC, which could have been perceived as a positive signal of investor interest at the time of its execution on April 3, 2025.
• The Intracoastal Warrant includes a blocker provision that prevents the holder from exercising it to the extent that it would result in beneficial ownership exceeding 4.99% of the Common Stock, which provides a safeguard against immediate significant dilution without prior stockholder approval.

Negatives

• Despite a deemed 9.6% beneficial ownership on April 3, 2025, the Reporting Persons reported zero beneficial ownership as of April 9, 2025, indicating a rapid change in their stake or the non-completion of the initial share issuance.
• The non-exercisability of the 310,000 share warrant until stockholder approval introduces uncertainty regarding the full extent of the investment and potential future dilution.

Risks

• The rapid change from 9.6% deemed beneficial ownership to 0% within a week by the Reporting Persons could signal unforeseen issues with the underlying Securities Purchase Agreement or a change in the investors' strategy, potentially impacting market perception.
• The contingent nature of the Intracoastal Warrant's exercisability, dependent on stockholder approval and subject to a 4.99% blocker, introduces uncertainty regarding future capital infusion or dilution from this specific instrument.

Future Outlook

The exercisability of the 310,000 shares underlying the Intracoastal Warrant is contingent upon the effective date of stockholder approval for the issuance of these shares. Additionally, a blocker provision limits the exercise if it would result in beneficial ownership exceeding 4.99%.

Industry Context

This Schedule 13G filing is a standard regulatory disclosure of significant ownership changes by passive investors. It does not provide broader industry trends or competitive analysis but reflects specific investment activity in Aptevo Therapeutics Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: The issuance of new shares and warrants under the Securities Purchase Agreement could lead to dilution. The rapid change in beneficial ownership by the Reporting Persons from 9.6% to 0% could influence investor sentiment and potentially the stock price.
• Intracoastal Capital LLC: Their investment strategy and potential future stake in Aptevo Therapeutics Inc. are directly impacted by the terms of the warrant and the current 0% beneficial ownership.

Next Steps

• Stockholder approval is required for the issuance of shares upon exercise of the Intracoastal Warrant.

Key Dates

Keywords

Aptevo Therapeutics Inc., Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Securities Purchase Agreement, Common Stock, Warrant, SEC Filing, Investment Disclosure, Shareholder Stake